Griseofulvin

Griseofulvin is an antifungal drug. It is used both in animals and in humans, to treat ringworm infections of the skin and nails. It is derived from the mold Penicillium griseofulvum.

It is administered orally.

Griseofulvin is an antifungal agent first isolated from a Penicillium spp. in 1939. The compound is insoluble in water. It is effective after oral ingestion and reaches the skin and hair. It is deposited primarily in keratin precursor cells. Ingestion with a heavy meal and reduction in particle size enhances the absorption of griseofulvin.

Griseofulvin is currently produced by different companies. The microcystalline form is marketed as Grifulvin V™ (Ortho Dermatological). (Fulvicin U/F™ (Schering) and Grisactin™ (Wyeth-Ayerst), the other two microcrystalline products are no longer marketed.) Ultramicrocrystalline form is marketed as Gris-PEG™ (Pedinol). (Fulvicin P/G™ (Schering) and Grisactin Ultra™ (Wyeth-Ayerst), the other two ultramicrocrystalline products are no longer marketed.)

Usual Doses
The typical dose of microcrystalline form is 500-1000 mg/day. Ultramicrocrystalline form is administered at doses of 330-990 mg/day .

Side-Effects
Adverse reactions of griseofulvin are uncommon. Nausea, diarrhea, headache, skin eruptions and photosensitivity are occasionally observed. Hepatotoxicity and neurological side effects may rarely occur .